KR101658377B1 - Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same - Google Patents
Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same Download PDFInfo
- Publication number
- KR101658377B1 KR101658377B1 KR1020100011690A KR20100011690A KR101658377B1 KR 101658377 B1 KR101658377 B1 KR 101658377B1 KR 1020100011690 A KR1020100011690 A KR 1020100011690A KR 20100011690 A KR20100011690 A KR 20100011690A KR 101658377 B1 KR101658377 B1 KR 101658377B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus plantarum
- yml
- larvae
- american
- yml001
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 32
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 32
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims description 9
- 230000000813 microbial effect Effects 0.000 title claims description 9
- 244000052769 pathogen Species 0.000 title claims description 7
- 230000001717 pathogenic effect Effects 0.000 title description 5
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 241000193418 Paenibacillus larvae Species 0.000 claims description 12
- 230000000845 anti-microbial effect Effects 0.000 claims description 11
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 241001330003 Paenibacillus larvae subsp. larvae Species 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 108010067770 Endopeptidase K Proteins 0.000 claims description 4
- 241000257303 Hymenoptera Species 0.000 claims description 4
- 108090001060 Lipase Proteins 0.000 claims description 4
- 239000004367 Lipase Substances 0.000 claims description 4
- 102000004882 Lipase Human genes 0.000 claims description 4
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 4
- 235000019421 lipase Nutrition 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 239000004382 Amylase Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 abstract description 31
- 102000004190 Enzymes Human genes 0.000 abstract description 12
- 108090000790 Enzymes Proteins 0.000 abstract description 12
- 239000003242 anti bacterial agent Substances 0.000 abstract description 12
- 238000009341 apiculture Methods 0.000 abstract description 12
- 230000003115 biocidal effect Effects 0.000 abstract description 8
- 235000012907 honey Nutrition 0.000 abstract description 6
- 241000710781 Flaviviridae Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 description 23
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000193830 Bacillus <bacterium> Species 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000004098 Tetracycline Substances 0.000 description 9
- 229960002180 tetracycline Drugs 0.000 description 9
- 229930101283 tetracycline Natural products 0.000 description 9
- 235000019364 tetracycline Nutrition 0.000 description 9
- 150000003522 tetracyclines Chemical class 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000013081 phylogenetic analysis Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
- Y10S435/857—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
본 발명은 락토바실러스 플란타룸 YML 001(Lactobacillus plantarum YML 001)에 관한 것으로, 보다 상세하게는 미국부저병(American Foulbrood)의 원인균인 패니바실러스 유충의 생육을 효과적으로 억제하고 고온과 산성·알칼리 조건, 여러 효소에 대해 안정성을 가지는 락토바실러스 플란타룸 YML 001에 관한 것이다.
본 발명에 따른 락토바실러스 플란타룸 YML 001은 양봉산업에 있어 큰 질병인 미국 부저병으로 인한 봉군 붕괴 및 수확되는 벌꿀의 품질의 저하 현상을 예방하고 치료할 수 있는 미생물제제로서 사용가능하며, 특히 항생제 남용으로 인한 항생제 잔류 벌꿀 제품에 대한 문제를 해결할 수 있는 항생제 대체물로서 양봉 사료의 첨가물, 양봉 약품으로 유용하게 사용될 수 있다.The present invention relates to Lactobacillus plantarum YML 001, and more particularly to a Lactobacillus plantarum YML 001 inhibitor which effectively inhibits the growth of Flaviviridae, a causative organism of American Foulbrood, Lactobacillus plantarum YML001 which has stability against various enzymes.
Lactobacillus plantarum YML 001 according to the present invention can be used as a microorganism preparation capable of preventing and treating the degradation of the quality of honey to be harvested and the collapse of the swine caused by the American buzzing disease which is a serious disease in the beekeeping industry. Antibiotic residues due to abuse As an antibiotic substitute that can solve problems with honey products, it can be usefully used as an additive for beekeeping feeds, bee-keeping drugs.
Description
본 발명은 미국부저병(American Foulbrood)의 원인균에 대한 항균활성을 가지는 락토바실러스 플란타룸 YML 001, 상기 미생물을 함유하는 항균성 미생물제제 및 상기 미생물을 이용한 방제방법에 관한 것이다.The present invention relates to Lactobacillus plantarum YML 001 having an antibacterial activity against a causative microorganism of American Foulbrood, an antimicrobial microorganism preparation containing the microorganism, and a method of controlling the microorganism using the microorganism.
국내·외 양봉 사육 현장에서 발생하는 중요한 전염병인 미국부저병은 패니바실러스 유충(Paenibacillus larvae subsp. larvae)에 의해서 일어나며, 발생 시기는 주로 봉군 이동기이다. 우리나라 양봉업의 기반이 되고 있는 아까시 꽃이 기후의 변동으로 더워지는 기후에 꽃은 피는데 꿀 생산량이 감소함에 따라서 이것을 보충하려고 업자들이 설탕을 대량으로 급여하고 있고 이에 따라서 벌의 건강상태가 허약해져 질병에 쉽게 노출된다. 뿐만 아니라 애벌레와 성충의 질병이 많고, 진드기의 항생제 내성이 증가하여 뚜렷한 대책이 없는 상태이다. Domestic and US buzzer important disease epidemics that occurred in other bee breeding field takes place by Fannie Bacillus larvae (Paenibacillus larvae subsp. Larvae), onset is usually bonggun mover. As the production of honey from the flowers in the climate that warms up due to the fluctuation of the climate, which is the base of the beekeeping industry in Korea, the honey is being supplied in large quantities by the workers to supplement it as the production of honey decreases, It is easily exposed. In addition, there are many diseases of larvae and adults, and there is no clear countermeasure due to increased antibiotic resistance of ticks.
주요 병적 증상으로는 유개봉 유충만이 발병하며 죽은 유충은 액화가 된다. 미국 부저병의 원인균은 주로 유충에 기생하며 유충의 폐사율이 증가함에 따라 봉군 자체의 붕괴를 야기하는 심각한 질병이다. The main pathological symptoms are only open larvae, and dead larvae are liquefied. The causative organism of American buzzers is largely parasitic on larvae and is a serious disease causing the collapse of the progeny itself as the larval mortality rate increases.
미국 부저병은 미생물성 질병으로 주로 항생제를 투여하여 치료를 하는데 패니바실러스 유충의 항생제 내성 균주 생성 및 양봉 부산물내 항생제 잔존의 문제가 발생하게 된다. 양봉에서 얻어지는 생산물로서 꿀, 프로폴리스 등은 대개 식품으로 이용되는 양봉 부산물 내 항생제 잔존 문제가 발생하게 된다. 미국 부저병의 감염 및 치료를 위해 항생제가 사용되고 있으나 항생제의 사용에 의한 부작용 또한 발생할 수 있다는 문제점이 있다. The American buzzers disease is a microbial disease mainly treated with antibiotics, which causes the generation of antibiotic resistant strains of Fanny Bacillus larvae and the remaining antibiotics in the beekeeping byproducts. Honey, propolis, etc., as a product obtained from beekeeping, usually cause the problem of residual antibiotics in beekeeping by-products used as food. Although antibiotics are used for infection and treatment of American buzzers, side effects due to the use of antibiotics may also occur.
또한 현재는 항생제 잔존량에 대한 규제가 갈수록 엄격해지고 있으므로 계속적인 항생제의 사용 및 남용은 제고해야 할 문제로 이미 대두되어 왔다. 이에 대한 대안으로 현재 미생물제제(Probiotics)에 대한 관심이 증대되고 있다.Also, since the regulations on the residual amount of antibiotics are becoming increasingly strict, current use of antibiotics and abuse have been raised as problems. As an alternative to this, interest in microbiological agents (probiotics) is increasing.
인체 및 동물체의 장내에는 다양한 미생물들이 존재하면서 장내의 미생물 균총을 이루고 있다. 이러한 미생물 중에는 숙주 동물에 유용한 것으로 알려진 유산균 등의 유익한 미생물들이 있는가 하면 반대로 숙주에 직접적 또는 잠재적인 유해성을 가지는 대장균, 살모넬라, 포도상구균 등의 미생물들이 또한 포함된다. 인체 및 동물체의 경우 스트레스의 증가, 유해 세균의 감염 등의 외부 환경의 변화에 의해서 장내 미생물의 균총이 파괴될 경우 유해 미생물들의 급격한 성장으로 이어져 숙주동물의 건강상태를 악화시키거나 설사에서부터 심지어는 폐사의 위험으로까지 진행될 수 있다.There are various microorganisms in the intestines of human and animal, and they form microorganisms in the intestines. Among these microorganisms are beneficial microorganisms such as lactic acid bacteria known to be useful in host animals and microorganisms such as Escherichia coli, Salmonella and Staphylococcus which directly or indirectly have potential harm to the host. In the case of human and animal, when the intestinal microorganisms are destroyed by changes in the external environment such as increased stress and infection of harmful bacteria, it leads to rapid growth of harmful microorganisms, which deteriorates the health condition of the host animal, The risk can be advanced to.
이러한 일이 발생하였을 경우 치료의 목적으로 항생제를 투여하게 되나 이러한 항생제는 체외로 완전히 배설이 되지 않고 숙주 내에 잔존하게 되며 지속적인 투여 시 유해 미생물들이 내성을 가지게 되므로 효과적인 치료를 할 수 없게 되는 상황이 발생하게 된다.When this happens, antibiotics are administered for the purpose of treatment. However, these antibiotics are not completely excreted in the body and remain in the host. In case of continuous administration, the harmful microorganisms become resistant, .
인체 및 동물체와 마찬가지로 곤충인 꿀벌 또한 비슷한 결과를 초래할 것으로 예상하여 유산균을 생산하는 미생물제제를 이용하여 양봉에 무분별하게 사용되는 항생제의 대체제 개발이 중요하다.It is important to develop an antibiotic substitute that is used indiscriminately in beekeeping by using a microbial agent that produces lactic acid bacteria, as the insect bee, as well as humans and animals, expects similar results.
미생물제제는 인체나 동물체의 장내에 서식하는 유익한 미생물을 분리하여 제제화한 것으로, 호기성균군, 혐기성균군, 유산균, 효모균들이 사용되고 있으나 주로 유산균들이 주요 균주로 이용되고 있다. 이러한 유산균 프로바이오틱스는 항생제 남용으로 인해 발생할 수 있는 부작용을 일으키지 않고 유해 미생물의 감염으로 인한 질병을 사전에 억제할 수 있다. Microorganism preparations are prepared by separating beneficial microorganisms living in the intestines of humans and animals. Aerobic bacteria, anaerobic bacteria, lactic acid bacteria and yeast bacteria are used, but lactic acid bacteria are mainly used as a major strain. These lactic acid probiotics can prevent diseases caused by infection with harmful microorganisms without causing side effects that may be caused by antibiotic abuse.
지금까지 미생물제제 프로바이오틱스로 다양한 종류의 유산균이 연구되어 왔으며, 특히 꿀벌의 장내 유용균인 비피더스균, 유산간균 및 유산구균을 혼합한 양봉사료 및 그 사용방법이 보고된 바 있다(대한민국 특허 제67946호).Various types of lactic acid bacteria have been studied with the microbiological preparation probiotics, and in particular, bee-bred diets mixed with bifidobacteria, lactic acid bacterium, and lactic acid bacteria, and methods of using them have been reported (Korean Patent No. 67946) .
이에 본 발명자들은 기존의 발표된 비피더스균 등을 혼합한 양봉사료를 이용하여 꿀벌의 면역기능을 증진시키는 것보다 꿀벌에 질병을 일으키는 직접적인 미국부저병의 원인균인 패니바실러스 유충을 억제하는 항균활성을 지닌 신규 미생물을 발견함으로써 본 발명을 완성하였다.Accordingly, the present inventors have found that the use of bee-bait mixed with existing bifidobacteria has an antimicrobial activity that inhibits Fanny Bacillus larva, which is a causative agent of direct American buzzers causing diseases in bees, rather than promoting the immune function of bees The present invention has been accomplished by discovering new microorganisms.
본 발명의 목적은 기존 항생제의 대체용으로 꿀벌에게 투여하는 양봉용 사료 첨가제, 양봉 약품 등에 사용하여 미국부저병(American Foulbrood)의 원인균인 패니바실러스 유충(Paenibacillus larvae subsp. larvae)을 억제할 수 있는 내열성, 내산성 미생물, 이를 함유하는 미생물제제 및 이를 이용한 방제방법을 제공하는 데에 있다.An object of the present invention is the heat resistance capable of suppressing the Companion Bacillus larvae (Paenibacillus larvae subsp. Larvae) cause of use or the like for beekeeping, feed additives, beekeeping drug administered to bees as a replacement of an existing antibiotic US buzzer disease (American Foulbrood) , An acid-resistant microorganism, a microorganism preparation containing the same, and a method of controlling the same.
상기 목적을 달성하기 위하여, 본 발명은 미국부저병(American Foulbrood)의 원인균에 대한 항균활성을 가지는 락토바실러스 플란타룸 YML 001(Lactobacillus plantarum YML 001)을 제공한다.In order to achieve the above object, the present invention provides Lactobacillus plantarum YML 001 having antimicrobial activity against causative bacteria of American Foulbrood.
상기 원인균은 패니바실러스 유충(Paenibacillus larvae subsp. larvae)이며, 상기 락토바실러스 플란타룸 YML 001은 내열성 및 내산성을 가지면서, 효소에 대하여 안정성을 갖는다. 또한, 상기 락토바실러스 플란타룸 YML 001은 최적온도 30℃-37℃에서 배양될 수 있다.The causative organism is a Bacillus larvae Companion (Paenibacillus larvae subsp. Larvae), the Lactobacillus Planta room YML 001 is while maintaining the heat resistance and acid resistance, has a stability against enzyme. In addition, the lactobacillus plantarum YML001 can be cultured at an optimum temperature of 30 ° C to 37 ° C.
상기 락토바실러스 플란타룸 YML 001의 16S rRNA 유전자의 염기 서열은 서열번호 1로 표시되며, 수탁번호 KCTC11627BP 로 기탁된 것이다.The base sequence of the 16S rRNA gene of Lactobacillus plantarum YML 001 is shown in SEQ ID NO: 1 and deposited with accession number KCTC11627BP.
또한, 본 발명은 상기 락토바실러스 플란타룸 YML 001을 함유하는 항균성 미생물제제를 제공한다. 상기 미생물제제는 양봉 사료 첨가제나 양봉 약품의 형태로 제공될 수 있다.The present invention also provides an antibacterial microorganism preparation containing the lactobacillus plantarum YML 001. The microbial formulation may be provided in the form of a bee feed additive or a bee-keeping drug.
또한, 본 발명은 상기 항균성 미생물제제을 이용한 미국부저병(American Foulbrood)의 방제방법을 제공한다.The present invention also provides a method for controlling American Foulbrood using the above-mentioned antibacterial microorganism preparation.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서는 미국부저병(American Foulbrood)의 원인균인 패니바실러스 유충을 억제할 수 있는 내열성, 내산성의 신규 미생물 락토바실러스 플란타룸 YML 001을 제공한다.The present invention provides a novel microbial lactobacillus plantarum YML 001 which is capable of inhibiting Fanny Bacillus larva, which is a causative organism of American Foulbrood, and which is resistant to heat and acid.
상기 균주는 패니바실러스 유충을 억제하는 미생물을 탐색한 결과, 얻어진 새로운 락토바실러스 플란타룸 균주로서 패니바실러스 유충의 억제 능력이 우수하면서 내열성, 내산성을 지니고 있다.As a result of searching for a microorganism inhibiting the Fanny Bacillus larva, the strain is a novel Lactobacillus planta room strain, and has excellent heat-ability and acid resistance.
구체적으로, 본 발명의 균주 락토바실러스 플란타룸 YML 001이 원인균인 패니바실러스 유충의 생장을 억제하는 억제환의 지름(단위는 mm)은 약 18mm로서, 대조군으로 100ppm 농도의 테트라사이클린 50㎕을 사용한 억제환의 지름(약 17mm)과 유사한 항균 활성을 나타내었다. Specifically, the diameter (unit: mm) of the inhibitory ring that inhibits the growth of Fanny Bacillus larvae causing the strain Lactobacillus plantarum YML 001 of the present invention was about 18 mm, and the inhibition using 50 μl of tetracycline at a concentration of 100 ppm as a control group And exhibited antibacterial activity similar to the diameter of the ring (about 17 mm).
본 발명에 따른 락토바실러스 플란타룸 YML 001이 미국부저병의 원인균의 생장을 억제하기 위한 최적 배양온도는 30-37℃이었다.The optimal incubation temperature for inhibiting the growth of causative microorganisms of US buzzers was 30-37 DEG C according to the present invention.
본 발명의 락토바실러스 플란타룸 YML 001 균주의 상등액은 각종 효소와 고온의 열, pH 변화에 대한 감수성이 적은 것으로 확인되었다. 구체적으로, 본 발명에 따른 락토바실러스 플란타룸 YML 001 상등액의 효소에 대한 감수성 실험은 프로티에이즈-케이(Protease K), 펩신(pepsin), 트립신(trypsin), 알파-아밀레이즈(a-amylase), 리페이즈(lipase) 등의 5종의 효소에 대하여 실행하였으며 효소에 대한 감수성은 매우 적었다.It was confirmed that the supernatant of Lactobacillus plantarum YML 001 strain of the present invention is insensitive to various enzymes and high temperature heat and pH changes. Specifically, the susceptibility test of the Lactobacillus plantarum YML 001 supernatant to the enzyme according to the present invention was performed using Protease K, pepsin, trypsin, a-amylase ) And lipase, and the sensitivity to the enzyme was very low.
고온의 열과 pH 변화에 대한 락토바실러스 플란타룸 YML 001 상등액의 감수성 실험은 배양 온도보다 높은 온도에서 시간별로 달리 열처리를 하였고, pH는 각기 다른 pH 범위의 버퍼(buffer)를 사용하여 실험하였으며, 락토바실러스 플란타룸 YML 001 상등액은 열처리와 pH 변화에 대한 감수성이 매우 적었다.The susceptibility test of Lactobacillus plantarum YML 001 supernatant to high temperature heat and pH changes was carried out at different temperatures over time at higher temperature than the incubation temperature and the pH was tested using buffer of different pH range, The Bacillus planta YML 001 supernatant was very insensitive to heat treatment and pH changes.
본 발명에 따른 락토바실러스 플란타룸 YML 001의 형태 및 생리학적 특성은 다음과 같다.The morphology and physiological characteristics of Lactobacillus plantarum YML001 according to the present invention are as follows.
락토바실러스 플란타룸 YML 001은 그람양성의 세균으로, 호기적인 조건과 혐기적인 조건에서 동시에 성장하며 포자를 형성하지 않고 운동성이 없으며, 세포의 형태는 간균이다. 상기 균주의 성장을 위한 최적온도는 30-37℃인 것이 바람직하다. Lactobacillus plantarum YML 001 is a gram - positive bacterium that grows simultaneously under aerobic conditions and anaerobic conditions, does not form spores and has no motility, and the cell type is bacillus. The optimum temperature for the growth of the strain is preferably 30-37 ° C.
본 발명의 락토바실러스 플란타룸 YML 001의 16S rRNA 유전자의 염기 서열은 서열번호 1로 기재되며, 16S rDNA 염기서열에 기초한 분자계통분류학적 분석을 통하여 본 발명의 균주는 락토바실러스(Lactobacillus) 속에 속하는 균주로서 99%의 16S rDNA 상동성으로 락토바실러스 플란타룸(Lactobacillus plantarum)의 표준균주에 가장 높은 분자계통학적 유연관계를 보여주는 균주로 동정되었다.The nucleotide sequence of the 16S rRNA gene of Lactobacillus plantarum YML 001 of the present invention is shown in SEQ ID NO: 1. Through the molecular phylogenetic analysis based on the 16S rDNA nucleotide sequence, the strain of the present invention belongs to the genus Lactobacillus As a strain, 99% of 16S rDNA homology was identified as a strain showing the highest molecular phylogenetic relationship to the standard strain of Lactobacillus plantarum .
따라서, 상기의 결과에 기초하여 본 발명의 균주를 락토바실러스 플란타룸(Lactobacillus plantarum)의 새로운 균주로 동정하고, 생물자원센터에 2010년 2월 1일자로 기탁하였다(수탁번호: KCTC11627BP).Therefore, based on the above results, the strain of the present invention was identified as a new strain of Lactobacillus plantarum and deposited on February 1, 2010 (Accession No .: KCTC11627BP) in the BRC.
또한, 본 발명은 락토바실러스 플란타룸 YML 001을 함유하는 미생물제제를 제공한다. 상기 미생물제제는 양봉사료 첨가제 또는 양봉약품 등의 형태로 제공될 수 있다.The present invention also provides a microorganism preparation containing Lactobacillus plantarum YML 001. The microbial agent may be provided in the form of a bee-growing feed additive or a bee-making drug.
본 발명의 미생물은 장기간 안정적으로 보존하기 위해 글리세롤 성분을 포함하여 -80℃에 보관하거나 멸균된 10% 탈지유에 현탁하여 동결건조하는 것이 바람직하다.The microorganism of the present invention is preferably stored at -80 DEG C containing glycerol component or suspended in sterilized 10% skim milk for freeze-drying for long-term stable storage.
또한, 본 발명은 락토바실러스 플란타룸 YML 001을 이용하여 미국부저병의 원인균인 패니바실러스 유충을 억제할 수 있는 미국부저병의 방제방법을 제공한다.In addition, the present invention provides a method for controlling American buzzers that can inhibit Fanny Bacillus larva, a causative organism of American buzzers, using Lactobacillus plantarum YML 001.
상기 방제방법에서, 락토바실러스 플란타룸 YML 001이 패니바실러스 유충을 억제하기 위한 최적 온도는 30-37℃인 것이 바람직하다.In the above-mentioned control method, it is preferable that the optimal temperature for suppressing the L. vulnificus YML 001 larva is 30-37 ° C.
본 발명에 따른 락토바실러스 플란타룸 YML 001은 미국 부저병의 원인균인 패니바실러스 유충을 효과적으로 억제하고 내열성, 내산성 기능을 가지고 있어 기존 항생제의 잔류, 오염 등의 문제를 대체 수 있는 환경친화적인 생물농약으로서의 고부가가치산물로 경제적 활용성이 증대될 것이다.Lactobacillus plantarum YML 001 according to the present invention effectively suppresses Fanny Bacillus larva, which is a causative organism of the American buzzers disease, and has heat and acid-proof functions, thereby being able to replace the existing problems of residual antibiotics and contamination. As a high value-added product.
또한, 병원성 생물의 증식 억제 효과를 갖는 신기능 프로바이오틱스인 본 발명에 따른 미생물제제를 사용함으로써 항생제 내성균의 출현을 효율적으로 차단하고 봉군의 꿀벌의 질병을 치료하거나 사전에 예방할 수 있다. In addition, by using the microorganism preparation according to the present invention, which is a new-function probiotics having an effect of inhibiting the growth of pathogenic organisms, the appearance of antibiotic resistant bacteria can be effectively blocked and the disease of bee bees in the bud can be treated or prevented in advance.
이하, 하기 실시예에 의해 본 발명을 보다 상세히 설명한다. 다만, 이러한 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 이러한 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are illustrative of the present invention, and the contents of the present invention are not limited by these examples.
<실시예 1> 산을 생성하는 성질을 가지는 미생물의 분리Example 1: Isolation of microorganisms having acid-producing properties
대구·경산 일대의 50여 곳에서 채집한 김치 1g을 0.85% 생리식염수(0.85g/100ml)에 십진희석하고 BCP 한천[2.5ｇ 건조 효모 추출물, 5.0ｇ 펩톤, 1.0ｇ 글루코오스, 0.1ｇ L-시스테인, 1.0ｇ 트윈80, 0.04ｇ 브로모크레졸 퍼플(Bromcresol purple: BCP), 15.0ｇ 한천 파우더, pH6.9±, EIKEN CHEMICAL]에 도말하여 30℃에서 48시간 동안 배양하였다. One gram of kimchi collected from 50 sites in Daegu and Gyeongsan area was decanted into 0.85% physiological saline (0.85g / 100ml) and BCP agar [2.5g dried yeast extract, 5.0g peptone, 1.0g glucose, 0.1g L-cysteine , 1.0 g Tween 80, 0.04 g Bromocresol purple (BCP), 15.0 g agar powder, pH 6.9, EIKEN CHEMICAL) and cultured at 30 ° C for 48 hours.
그 중 산을 생성한 콜로니를 다시 MRS 한천(10g 프로테오스 펩톤 No.3, 10g 쇠고기 추출물, 5g 효모 추출물, 20g 덱스트로오스, 5g 폴리솔베이트80, 5g 초산나트륨, 2g 구연산암모늄, 0.1g MnSO4, 0.05g MnSO4, 2g 제2인산칼륨)을 사용하여 약 1,800 여종의 산 생성균을 순수분리 하였고 보존은 30% 글리세롤(H2O:글리세롤＝7:3) 300㎕와 배양액 500㎕를 현탁하여 -70℃에 보존하였다. The acid-producing colonies were again suspended in MRS agar (10 g protease peptone No. 3, 10 g beef extract, 5 g yeast extract, 20 g dextrose, 5 g polysorbate 80, 5 g sodium acetate, 2 g ammonium citrate, MnSO 4 , 0.05 g MnSO 4 , 2 g potassium phosphate) were used to purify about 1,800 acid-producing bacteria. To store, 300 μl of 30% glycerol (H 2 O: glycerol = 7: 3) Suspended and stored at -70 ° C.
<실시예 2> 분리된 미생물의 항균 활성 검토<Example 2> Examination of antibacterial activity of isolated microorganisms
본 발명에 사용된 미국부저병의 원인균인 패니바실러스 유충은 생물 자원센터에서 분양 받은 균으로, 기탁번호 KCTC3744 균주를 사용하였다.The Fanny Bacillus larva, which is a causative organism of the US buzzer disease used in the present invention, was purchased from the BRC and the strain No. KCTC3744 was used.
1% 접종한 패니바실러스 유충을 BHI broth에서 24시간 동안 37℃, 호기적 조건에서 배양하고, 실시예 1에서 얻어진 실험에 사용된 분리균은 MRS broth에 48시간 동안 30℃, 호기적 조건에서 배양하였다. 분리균의 배양액은 12,000rpm에서 15분 동안 원심분리를 수행하여 상등액과 균체를 분리하였고, 상등액을 항균활성 시험에 사용하였다.The 1% inoculated Fanny Bacillus larvae were cultured in BHI broth for 24 hours at 37 ° C under aerobic conditions. The isolates used in the experiment obtained in Example 1 were cultured in MRS broth for 48 hours at 30 ° C under aerobic conditions Respectively. The culture broth of the isolate was centrifuged at 12,000 rpm for 15 minutes to separate the supernatant and cells, and the supernatant was used for the antimicrobial activity test.
1차 선별 단계로 96-well plate에 BHI broth를 100㎕씩 각 well에 분주하고 패니바실러스 유충 배양액을 50㎕를 분주하였다. 그 위에 분리균의 상등액 50㎕를 처리하였다. 양성대조군으로 100ppm 테트라사이클린(Generay Biotech)을 상등액과 동량으로 사용하였다. 테트라사이클린은 내성 균주가 생기기 전까지 양봉 항균제로 사용되었으며 아직도 몇몇 양봉업에서는 사용하고 있다. 본 발명에서 사용한 패니바실러스 유충은 내성이 생기지 않은 균주이기에 테트라사이클린을 사용하였다. 100 μl of BHI broth was dispensed into each well in a 96-well plate and 50 μl of Fanny Bacillus larva culture was dispensed. And 50 占 퐇 of the supernatant of the isolated bacteria was treated. As a positive control, 100 ppm tetracycline (Generay Biotech) was used in the same amount as the supernatant. Tetracycline has been used as a bee - tanning antibiotic until a resistant strain has emerged and is still used by some beekeeping companies. Tetracycline was used because the Fanny Bacillus larva used in the present invention was a strain that did not develop resistance.
처리가 끝난 96-well plate를 37℃에서 24시간 동안 배양하고 분광광도계(NanoBometer OPTIZEN 3220UV, Mecasys Co.)를 이용하여 OD 600nm에서 흡광도 값을 측정하였다.The treated 96-well plate was incubated at 37 ° C for 24 hours and absorbance was measured at OD 600nm using a spectrophotometer (NanoBometer OPTIZEN 3220UV, Mecasys Co.).
1차 시험에서 선발된 후보 균주는 2차 시험으로 페이퍼 디스크 항균활성 시험을 수행하였다. 앞선 시험과 같이 패니바실러스 유충을 BHI broth에서 24시간 동안 37℃, 호기적 조건에서 배양하고, 테스트에 사용된 분리균은 MRS broth에 48시간 동안 30℃, 호기적 조건에서 배양하였다. 패니바실러스 유충 배양액 400㎕을 BHI 한천 배지에 도말하고, 페이퍼 디스크에 분리균의 상등액 500㎕을 10배 농축하여 처리하였고 양성대조군으로 100ppm 테트라사이클린(100ppm) 50㎕을 사용하였다. 모든 처리가 끝난 플레이트를 37℃에서 24시간 동안 배양하고 클리어존(clear zone)의 직경을 측정하였다.Candidate strains selected in the first test were subjected to a paper disk antimicrobial activity test as a secondary test. Fanny Bacillus larvae were cultured in BHI broth for 24 hours at 37 ℃ under aerobic conditions. The isolates used for the test were cultured in MRS broth for 48 hours at 30 ℃ under aerobic conditions. 400 μl of Fanny Bacillus larvae culture was plated on BHI agar medium and 500 μl of the supernatant of the isolate was concentrated on a paper disk by 10 times and treated with 50 μl of 100 ppm tetracycline (100 ppm) as a positive control. All treated plates were incubated at 37 ° C for 24 hours and the diameter of the clear zone was measured.
상기 분리균 1,800개 중에서 가장 항균활성이 우수한 것을 YML 001로 명명하였으며, YML 001의 패니바실러스 유충에 대한 억제 활성을 시간별로 측정하기 위하여 3시간 단위로 배양액을 취하여 항균활성 시험을 하였다.Of the 1,800 isolates, YML 001 was named as the most excellent antimicrobial activity. In order to measure the inhibitory activity of YML 001 against the Fanny Bacillus larvae, the culture broth was taken every 3 hours and tested for antibacterial activity.
병원균의 생육 억제를 확인하기 위하여 OD 600nm에서 흡광도를 측정하였고, 21시간째에 항균활성이 가장 우수하였다. 그 결과를 하기 표 1 에 나타내었다.The absorbance at OD 600nm was measured to confirm inhibition of pathogen growth, and the antimicrobial activity was the best at 21 hours. The results are shown in Table 1 below.
<실시예 3> YML 001 상등액의 효소에 대한 감수성 실험<Example 3> Sensitivity test for the enzyme of the supernatant of YML 001
YML 001 상등액의 효소에 대한 감수성 실험에 사용된 효소의 종류는 프로티에이즈-케이(Protease K), 펩신(pepsin), 트립신(trypsin), 알파-아밀레이즈(a-amylase), 리페이즈(lipase) 등으로 이들을 적절한 용매에 용해하여 사용하였다. 준비한 효소를 50㎕씩 10배 농축한 YML 001 상등액 50 ㎕와 혼합하여 각 효소의 반응 온도에서 3시간 동안 반응시킨 후, 효소를 불활성화하기 위하여 100℃에서 10분간 처리를 한 뒤 패니바실러스 유충에 대한 항균활성 실험을 수행하였고 그 결과는 표 2와 같다. The sensitivity of the YML 001 supernatant to the enzymes was determined by the following enzymes: Protease K, pepsin, trypsin, a-amylase, lipase ) Were dissolved in an appropriate solvent and used. The prepared enzyme was mixed with 50 μl of YML 001 supernatant, which was 10-fold concentrated by 50 μl, and reacted for 3 hours at the reaction temperature of each enzyme. The enzyme was then treated at 100 ° C. for 10 minutes to inactivate the enzyme, The results of the antimicrobial activity tests are shown in Table 2.
<실시예 4> YML 001 상등액의 열, pH 변화에 대한 감수성 실험<Example 4> Sensitivity test for heat and pH change of the supernatant of YML 001
10배 농축된 YML 001 상등액을 50℃, 70℃, 100℃의 각 온도에서 10분, 20분, 30분, 60분 / 121℃에서 15분 동안 열처리를 하여 페이퍼 디스크 분석을 수행한 결과를 표 3에 나타내었다.10-fold concentrated YML 001 supernatant was heat-treated at 50 ° C, 70 ° C and 100 ° C for 10 minutes, 20 minutes, 30 minutes, 60 minutes and 121 ° C for 15 minutes, Respectively.
또한, pH 조정은 각 pH에 해당하는 완충액을 0.2M로 조정해 농축된 상등액에 처리하여 24시간 동안 반응 후 pH 6.5로 조정하여 페이퍼 디스크 분석을 수행한 결과를 표 4에 나타내었다.The pH of the solution was adjusted to 0.2 M by adjusting the pH of the buffer solution to pH 6.5 after 24 hours of treatment with the concentrated supernatant.
<실시예 5> 선발한 미생물 YML001의 동정≪ Example 5 > Identification of the selected microorganism YML001
상기 실시예 2에서 선발된 YML 001 균주를 MRS 배지(Difco사 제품)에서 30℃ 조건으로 배양하였다. YML 001 균주를 동정하기 위하여, 16S rDNA 유전자의 염기서열 결정 및 분석은 1492R과 27F를 프라이머로 사용하였다.The YML 001 strain selected in Example 2 was cultured at 30 ° C in an MRS medium (Difco). In order to identify the YML 001 strain, the nucleotide sequence of the 16S rDNA gene was determined and analyzed using 1492R and 27F as primers.
YML001 16S rRNA 유전자의 염기 서열은 서열번호 1로 기재되며, 16S rDNA 염기서열에 기초한 분자계통분류학적 분석을 통하여 본 발명의 균주는 락토바실러스(Lactobacillus) 속에 속하는 균주로서 99%의 16S rDNA 상동성으로 락토바실러스 플란타룸(Lactobacillus plantarum)의 표준균주에 가장 높은 분자계통학적 유연관계를 보여주는 균주로 동정되었다.The nucleotide sequence of the YML001 16S rRNA gene is shown in SEQ ID NO: 1, and through the molecular phylogenetic analysis based on the 16S rDNA nucleotide sequence, the strain of the present invention is a strain belonging to the genus Lactobacillus and has 99% 16S rDNA homology Lactobacillus plantarum was identified as the strain with the highest molecular phylogenetic relationship to the standard strain of Lactobacillus plantarum .
따라서, 상기의 결과에 기초하여 YML 001은 기존 미생물 제제와는 다른 락토바실러스 플란타룸(Lactobacillus plantarum)의 균주로 동정하고, 한국미생물보존센터에 2010년 2월 01일자로 기탁하였다(수탁번호: KCTC11627BP).Based on the above results, YML 001 was identified as a strain of Lactobacillus plantarum different from the existing microorganism preparation and deposited on Feb. 1, 2010 (Accession No: KCTC11627BP).
<110> Industry-Academic Cooperation Foundation, Yeungnam University <120> Lactobacillus plantarum YML 001 against pathogen of American Foulbrood, microbial agent comprising the same, and method for preventing pathogen using the same <130> DP-2010-0065 <160> 1 <170> KopatentIn 1.71 <210> 1 <211> 1467 <212> DNA <213> Artificial Sequence <220> <223> YML001 16S rRNA gene <400> 1 tnnnnnngct ngagctatac atgcaagtcg aacgaactct ggtattgatt ggtgcttgca 60 tcatgattta catttgagtg agtggcgaac tggtgagtaa cacgtgggaa acctgcccag 120 aagcggggga taacacctgg aaacagatgc taataccgca taacaacttg gaccgcatgg 180 tccgagcttg aaagatggct tcggctatca cttttggatg gtcccgcggc gtattagcta 240 gatggtgggg taacggctca ccatggcaat gatacgtagc cgacctgaga gggtaatcgg 300 ccacattggg actgagacac ggcccaaact cctacgggag gcagcagtag ggaatcttcc 360 acaatggacg aaagtctgat ggagcaacgc cgcgtgagtg aagaagggtt tcggctcgta 420 aaactctgtt gttaaagaag aacatatctg agagtaactg ttcaggtatt gacggtattt 480 aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg 540 ttgtccggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag 600 ccttcggctc aaccgaagaa gtgcatcgga aactgggaaa cttgagtgca gaagaggaca 660 gtggaactcc atgtgtagcg gtgaaatgcg tagatatatg gaagaacacc agtggcgaag 720 gcggctgtct ggtctgtaac tgacgctgag gctcgaaagt atgggtagca aacaggatta 780 gataccctgg tagtccatac cgtaaacgat gaatgctaag tgttggaggg tttccgccct 840 tcagtgctgc agctaacgca ttaagcattc cgcctgggga gtacggccgc aaggctgaaa 900 ctcaaaggaa ttgacggggg cccgcacaag cggtggagca tgggtttaat tcgaagctac 960 gcgaagaacc ttaccaggtc ttgacatact atgcaaatct agagattaga cgttcccttc 1020 ggggacatgg atacaggtgg tgcatggttg tcgtcagctc gtgtcgtgag atgttgggtt 1080 aagtcccgca acgagcgcaa cccttattat cagttgccag cattaagttg ggcactctgg 1140 tgagactgcc ggtgacaaac cggaggaagg tggggatgac gtcaaatcat catgcccctt 1200 atgacctggg ctacacacgt gctacaatgg atggtacaac gagttgcgaa ctcgcgagag 1260 taagctaatc tcttaaagcc attctcagtt cggattgtag gctgcaactc gcctacatga 1320 agtcggaatc gctagtaatc gcggatcagc atgccgcggt gaatacgttc ccgggccttg 1380 tacacaccgc ccgtcacacc atgagagttt gtaacaccca aagtcggtgg ggtaaccttt 1440 taggaaccag cctgcataat ggngaca 1467 <110> Industry-Academic Cooperation Foundation, Yeungnam University <120> Lactobacillus plantarum YML 001 against pathogen of American Foulbrood, microbial agent comprising the same, and method for preventing pathogen using the same <130> DP-2010-0065 <160> 1 <170> Kopatentin 1.71 <210> 1 <211> 1467 <212> DNA <213> Artificial Sequence <220> <223> YML001 16S rRNA gene <400> 1 tnnnnnngct ngagctatac atgcaagtcg aacgaactct ggtattgatt ggtgcttgca 60 tcatgattta catttgagtg agtggcgaac tggtgagtaa cacgtgggaa acctgcccag 120 aagcggggga taacacctgg aaacagatgc taataccgca taacaacttg gaccgcatgg 180 tccgagcttg aaagatggct tcggctatca cttttggatg gtcccgcggc gtattagcta 240 gatggtgggg taacggctca ccatggcaat gatacgtagc cgacctgaga gggtaatcgg 300 ccacattggg actgagacac ggcccaaact cctacgggag gcagcagtag ggaatcttcc 360 acaatggacg aaagtctgat ggagcaacgc cgcgtgagtg aagaagggtt tcggctcgta 420 aaactctgtt gttaaagaag aacatatctg agagtaactg ttcaggtatt gacggtattt 480 aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg 540 ttgtccggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag 600 ccttcggctc aaccgaagaa gtgcatcgga aactgggaaa cttgagtgca gaagaggaca 660 gtggaactcc atgtgtagcg gtgaaatgcg tagatatatg gaagaacacc agtggcgaag 720 gcggctgtct ggtctgtaac tgacgctgag gctcgaaagt atgggtagca aacaggatta 780 gataccctgg tagtccatac cgtaaacgat gaatgctaag tgttggaggg tttccgccct 840 tcagtgctgc agctaacgca ttaagcattc cgcctgggga gtacggccgc aaggctgaaa 900 ctcaaaggaa ttgacggggg cccgcacaag cggtggagca tgggtttaat tcgaagctac 960 gcgaagaacc ttaccaggtc ttgacatact atgcaaatct agagattaga cgttcccttc 1020 ggggacatgg atacaggtgg tgcatggttg tcgtcagctc gtgtcgtgag atgttgggtt 1080 aagtcccgca acgagcgcaa cccttattat cagttgccag cattaagttg ggcactctgg 1140 tgagactgcc ggtgacaaac cggaggaagg tggggatgac gtcaaatcat catgcccctt 1200 atgacctggg ctacacacgt gctacaatgg atggtacaac gagttgcgaa ctcgcgagag 1260 taagctaatc tcttaaagcc attctcagtt cggattgtag gctgcaactc gcctacatga 1320 agtcggaatc gctagtaatc gcggatcagc atgccgcggt gaatacgttc ccgggccttg 1380 tacacaccgc ccgtcacacc atgagagttt gtaacaccca aagtcggtgg ggtaaccttt 1440 taggaaccag cctgcataat ggngaca 1467
Claims (8)
Claims 7 to contain an antibacterial microbial preparation according to the bee feed additive or bee drug US buzzer bottle characterized in that to provide the bees inhibiting pathogens is Waist Bacillus larvae (Paenibacillus larvae subsp. Larvae) American buzzer disease (American Foulbrood ).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100011690A KR101658377B1 (en) | 2010-02-08 | 2010-02-08 | Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100011690A KR101658377B1 (en) | 2010-02-08 | 2010-02-08 | Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110092177A KR20110092177A (en) | 2011-08-17 |
| KR101658377B1 true KR101658377B1 (en) | 2016-09-21 |
Family
ID=44929158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100011690A KR101658377B1 (en) | 2010-02-08 | 2010-02-08 | Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101658377B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190070676A (en) | 2017-12-13 | 2019-06-21 | 대한민국(환경부 국립생물자원관장) | Lactobacillus plantarum having antibacterial activity and uses thereof |
| KR20200115794A (en) | 2019-03-26 | 2020-10-08 | 주식회사 코젠바이오텍 | Primers and probes for detection of sacbrood virus, Paenibacillus larvae and Melissococcus plutonius, and method for detecting sacbrood virus, Paenibacillus larvae and Melissococcus plutonius using the same |
| KR20200134682A (en) | 2019-05-23 | 2020-12-02 | 대한민국(환경부 국립생물자원관장) | Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof |
| KR20210078251A (en) | 2019-12-18 | 2021-06-28 | 대한민국(환경부 국립생물자원관장) | Anti-Microbial Peptide Plantaricin, Isolated from Lactobacillus Plantarum and Uses thereof |
| KR102353992B1 (en) | 2020-12-10 | 2022-01-24 | 대한민국 | Lactobacillus plantarum NIBR K9 Having Anti-Microbial and Anti-Viral Activity, Anti-Microbial and Anti-Viral Peptides Isolated from the Same, Uses thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101348435B1 (en) * | 2011-12-08 | 2014-01-09 | 영남대학교 산학협력단 | Lactobacillus plantarum YML007 having anti-fungal activitiy and its use |
| KR101304073B1 (en) * | 2012-01-05 | 2013-09-05 | 영남대학교 산학협력단 | Composition for Controlling vermins related to bee |
| KR101695918B1 (en) | 2015-06-23 | 2017-01-12 | 경상대학교산학협력단 | Streptomyces badius SP6C4 strain having antimicirobial activity against insect pathogen or strawberry fungal disease pathogen isolated from strawberry pollen and uses thereof |
| EP3698643A1 (en) * | 2019-02-04 | 2020-08-26 | Pileckas, Juozas | The method of health maintaining and treating of the honey bee using herbal additives |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005132804A (en) | 2003-10-31 | 2005-05-26 | Jrj Pharmaceutical Co Ltd | Antimicrobial agent |
| US20060263344A1 (en) | 2003-04-02 | 2006-11-23 | Mitchell Skop | Novel probiotic compositions and methods of using the same |
| WO2008136730A1 (en) | 2007-05-03 | 2008-11-13 | Tobias Olofsson | Novel bacteria isolated from fresh honey or the honey producing tract of honey bees |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100557397B1 (en) * | 2003-09-05 | 2006-03-06 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus reuteri Probio-054 that can suppresses the growth of pathogenic microorganisms |
-
2010
- 2010-02-08 KR KR1020100011690A patent/KR101658377B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060263344A1 (en) | 2003-04-02 | 2006-11-23 | Mitchell Skop | Novel probiotic compositions and methods of using the same |
| JP2005132804A (en) | 2003-10-31 | 2005-05-26 | Jrj Pharmaceutical Co Ltd | Antimicrobial agent |
| WO2008136730A1 (en) | 2007-05-03 | 2008-11-13 | Tobias Olofsson | Novel bacteria isolated from fresh honey or the honey producing tract of honey bees |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190070676A (en) | 2017-12-13 | 2019-06-21 | 대한민국(환경부 국립생물자원관장) | Lactobacillus plantarum having antibacterial activity and uses thereof |
| KR20200115794A (en) | 2019-03-26 | 2020-10-08 | 주식회사 코젠바이오텍 | Primers and probes for detection of sacbrood virus, Paenibacillus larvae and Melissococcus plutonius, and method for detecting sacbrood virus, Paenibacillus larvae and Melissococcus plutonius using the same |
| KR20200134682A (en) | 2019-05-23 | 2020-12-02 | 대한민국(환경부 국립생물자원관장) | Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof |
| KR20210078251A (en) | 2019-12-18 | 2021-06-28 | 대한민국(환경부 국립생물자원관장) | Anti-Microbial Peptide Plantaricin, Isolated from Lactobacillus Plantarum and Uses thereof |
| KR102353992B1 (en) | 2020-12-10 | 2022-01-24 | 대한민국 | Lactobacillus plantarum NIBR K9 Having Anti-Microbial and Anti-Viral Activity, Anti-Microbial and Anti-Viral Peptides Isolated from the Same, Uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110092177A (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101658377B1 (en) | Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same | |
| Sarika et al. | Bacteriocin production by a new isolate of Lactobacillus rhamnosus GP1 under different culture conditions | |
| Li et al. | Identification and antimicrobial activity detection of lactic acid bacteria isolated from corn stover silage | |
| KR101142869B1 (en) | Microorganism formulation for preventing plant disease, comprising bacillus subtilis kb-401 as active ingredient | |
| KR102052056B1 (en) | Lactobacillus plantarum having antibacterial activity and uses thereof | |
| Gharib | Antimicrobial activity and probiotic properties of lactic acid bacteria isolated from traditional fermented dairy products | |
| KR20130113037A (en) | Novel bacillus subtilis | |
| US20090155417A1 (en) | Additive for animal feed | |
| WO2014084523A1 (en) | Health supplement food containing pediococcus acidilactici j9, and method for manufacturing same | |
| KR101498272B1 (en) | Bacillus subtilis strain isolated from Kimchi, producing antimicrobial substances and having immune activity, and probiotics composition using it | |
| EP3198040A1 (en) | Probiotic fermented feed additives | |
| KR101702499B1 (en) | Composition of formulated diets comprising novel lactic acid bacteria, fungus and bacterium | |
| KR101345248B1 (en) | Lactic acid bacteria for inhibiting the pathogenic bacteria and composition containing the same | |
| KR101047948B1 (en) | Lactobacillus Producing Bacteriocin and Probiotic Composition Containing the Same | |
| KR20210106930A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
| Balakrishna et al. | Screening of potential aquatic probiotics from the major microflora of guppies (Poecilia reticulata) | |
| KR100951273B1 (en) | Feed additive containing an extract of bamboo and microorganism cultivate,for prevention of Porcinediarrhea caused by enterotoxigenic enterobacteria | |
| KR101659062B1 (en) | Pediococcus parvulus against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same | |
| KR20150056208A (en) | A novel Lactobacillus fermentum SJ8256 and use thereof | |
| KR102109195B1 (en) | Natural bacteriocin produced by Lactobacillus brevis and it's gene sequences | |
| KR20160045278A (en) | A fermented feed additive composition using microorganism and a prepration method thereof | |
| KR102272419B1 (en) | Pediococcus pentosaceus KCC-45 an composition containing the same | |
| KR100886793B1 (en) | Novel Lactobacillus coryniformis HD-02 with antimicrobial and probiotic activity, and its use | |
| KR20080051798A (en) | Bacillus subtilis and probiotics using the same | |
| KR20170068694A (en) | Novel natural disinfectant with probiotics properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190708 Year of fee payment: 4 |